Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is evaluating how well imatinib mesylate works compared to
rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease
(GVHD). Both imatinib and rituximab have been reported to decrease skin thickening and
improve skin and joint flexibility in people with cutaneous sclerosis due to chronic GVHD.